Yesterday, Sept. 15, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $35.04 to $4,142,629.75.

Highlighted Stocks Traded by Insiders:

Renasant (RNST) - FREE Research Report

Johnson Stuart, who is Sevp at Renasant, sold 600 shares at $32.56 on Sept. 15, 2015. Following this transaction, the Sevp owned 8,732 shares meaning that the stake was reduced by 6.43% with the 600-share transaction.

The shares most recently traded at $32.58, up $0.02, or 0.06% since the insider transaction. Historical insider transactions for Renasant go as follows:

  • 4-Week # shares bought: 4,000
  • 4-Week # shares sold: 6,700
  • 12-Week # shares bought: 4,000
  • 12-Week # shares sold: 21,268
  • 24-Week # shares bought: 4,000
  • 24-Week # shares sold: 21,268

The average volume for Renasant has been 176,100 shares per day over the past 30 days. Renasant has a market cap of $1.3 billion and is part of the financial sector and banking industry. Shares are up 12.82% year-to-date as of the close of trading on Tuesday.

Renasant Corporation, through its subsidiaries, provides financial, fiduciary, and insurance services to retail and commercial customers. It operates through three segments: Community Banks, Insurance, and Wealth Management. The stock currently has a dividend yield of 2.09%. The company has a P/E ratio of 16.8. Currently, there are 4 analysts who rate Renasant a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on RNST - FREE

TheStreet Quant Ratings rates Renasant as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, expanding profit margins, solid stock price performance and increase in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Renasant Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Opko Health (OPK) - FREE Research Report

Logal Adam, who is Sr. Vice President, CFO at Opko Health, bought 1,000 shares at $9.95 on Sept. 15, 2015. Following this transaction, the Sr. Vice President, CFO owned 45,789 shares meaning that the stake was boosted by 2.23% with the 1,000-share transaction.

The shares most recently traded at $10.28, up $0.33, or 3.21% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 22,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 24,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 27,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 5.3 million shares per day over the past 30 days. Opko Health has a market cap of $4.7 billion and is part of the health care sector and drugs industry. Shares are up 3.4% year-to-date as of the close of trading on Tuesday.

OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics. Currently, there are 2 analysts who rate Opko Health a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Invesco Mortgage Capital (IVR) - FREE Research Report

King Richard J., who is President & CEO at Invesco Mortgage Capital, bought 1,450 shares at $13.42 on Sept. 15, 2015. Following this transaction, the President & CEO owned 104,402 shares meaning that the stake was boosted by 1.41% with the 1,450-share transaction.

Historical insider transactions for Invesco Mortgage Capital go as follows:

  • 4-Week # shares bought: 4,800
  • 12-Week # shares bought: 4,800
  • 24-Week # shares bought: 7,800

The average volume for Invesco Mortgage Capital has been 1.3 million shares per day over the past 30 days. Invesco Mortgage Capital has a market cap of $1.7 billion and is part of the financial sector and real estate industry. Shares are down 13.58% year-to-date as of the close of trading on Tuesday.

Invesco Mortgage Capital Inc., a real estate investment trust, focuses on investing in, financing, and managing residential and commercial mortgage-backed securities and mortgage loans. It invests in residential mortgage-backed securities for which a U.S. The stock currently has a dividend yield of 13.38%. Currently, there are 4 analysts who rate Invesco Mortgage Capital a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IVR - FREE

TheStreet Quant Ratings rates Invesco Mortgage Capital as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, expanding profit margins and good cash flow from operations. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Invesco Mortgage Capital Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.